<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLODERM- clocortolone pivalate cream </strong><br>Promius Pharma, LLC<br></p></div>
<h1>Cloderm<span class="Sup">®</span> Cream, 0.1% <br>(clocortolone pivalate) </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only</span></p>
<p><span class="Bold">FOR TOPICAL DERMATOLOGIC USE ONLY–NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE. <br>WARNING: KEEP OUT OF REACH OF CHILDREN</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Cloderm Cream 0.1% contains the medium potency topical corticosteroid,
                     clocortolone pivalate, in a specially formulated water-washable emollient cream
                     base consisting of purified water, white petrolatum, mineral oil, stearyl
                     alcohol, polyoxyl 40 stearate, carbomer 934P, edetate disodium, sodium
                     hydroxide, with methylparaben and propylparaben as preservatives.</p>
<a name="table1"></a><table width="50%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr class="First Last">
<td class="Toprule" align="left">Chemically, clocortolone pivalate is <br>9-chloro-6α-fluoro-11β,
                              <br>21-dihydroxy-16α methylpregna-1, <br>4-diene-3, 20-dione
                              21-pivalate. <br>Its structure is as follows: <br>
</td>
<td class="Botrule" align="left"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4abc01f2-03d4-43d5-a085-f452443cfca2&amp;name=cloderm-01.jpg"></td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. </p>
<br><p>The mechanism of anti-inflammatory activity of the topical
                     corticosteroids is unclear. Various laboratory methods, including
                     vasoconstrictor assays, are used to compare and predict potencies and/or
                     clinical efficacies of the topical corticosteroids. There is some evidence to
                     suggest that a recognizable correlation exists between vasoconstrictor potency
                     and therapeutic efficacy in man.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1"></a><p></p>
<h2><span class="Italics">Pharmacokinetics:</span></h2>
<p class="First">The extent of percutaneous absorption of topical corticosteroids
                           is determined by many factors including the vehicle, the integrity of the
                           epidermal barrier, and the use of occlusive dressings.</p>
<br><p>Topical corticosteroids can be absorbed from normal intact skin.
                           <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and/or other disease processes in the skin increase
                           percutaneous absorption. Occlusive dressings substantially increase the
                           percutaneous absorption of topical corticosteroids. Thus, occlusive
                           dressings may be a valuable therapeutic adjunct for treatment of
                           resistant dermatoses. (See <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a>).</span></p>
<br><p>Once absorbed through the skin, topical corticosteroids are
                           handled through pharmacokinetic pathways similar to systemically
                           administered corticosteroids. Corticosteroids are bound to plasma
                           proteins in varying degrees. Corticosteroids are metabolized primarily in
                           the liver and are then excreted by the kidneys. Some of the topical
                           corticosteroids and their metabolites are also excreted into the
                        bile.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Topical corticosteroids are contraindicated in those patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components of the preparation.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2><span class="Italics">General:</span></h2>
<p class="First">Systemic absorption of topical corticosteroids has produced
                           reversible hypothalamic-pituitary-adrenal (HPA) axis suppression,
                           manifestations of Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria in
                           some patients.</p>
<br><p>Conditions which augment systemic absorption include the
                           application of the more potent steroids, use over large surface areas,
                           prolonged use, and the addition of occlusive dressings.</p>
<br><p>Therefore, patients receiving a large dose of a potent topical
                           steroid applied to a large surface area or under an occlusive dressing
                           should be evaluated periodically for evidence of HPA axis suppression by
                           using the urinary free cortisol and ACTH stimulation tests. If HPA axis
                           suppression is noted, an attempt should be made to withdraw the drug, to
                           reduce the frequency of application, or to substitute a less potent
                           steroid.</p>
<p>Recovery of HPA axis function is generally prompt and complete
                           upon discontinuation of the drug. Infrequently, signs and symptoms of
                           steroid withdrawal may occur, requiring supplemental systemic
                           corticosteroids.</p>
<br><p>Children may absorb proportionally larger amounts of topical
                           corticosteroids and thus be more susceptible to systemic toxicity. (See
                              <span class="Bold"><a href="#Pediatric">PRECAUTIONS</a></span>-<span class="Italics"><a href="#Pediatric">Pediatric Use</a></span>
                           ).</p>
<br><p>If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.</p>
<br><p>In the presence of dermatological <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the use of an
                           appropriate antifungal or antibacterial agent should be instituted. If a
                           favorable response does not occur promptly, the corticosteroid should be
                           discontinued until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been adequately
                        controlled.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.2"></a><p></p>
<h2><span class="Italics">Information for the Patient:</span></h2>
<p class="First">Patients using topical corticosteroids should receive the following information and instructions:</p>
<br><ol>
<li>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.</li>
<li>Patients should be advised not to use this medication for any disorder other than for which it was prescribed.</li>
<li>The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.</li>
<li>Patients should report any signs of local adverse reactions especially under occlusive dressing.</li>
<li>Parents of pediatric patients should be advised not to use
                              tight-fitting diapers or plastic pants on a child being treated in the
                              diaper area, as these garments may constitute occlusive
                           dressings.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-6.3"></a><p></p>
<h2><span class="Italics">Laboratory Tests:</span></h2>
<p class="First">The following tests may be helpful in evaluating the HPA axis suppression:<br> Urinary free cortisol test<br> ACTH stimulation test</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.4"></a><p></p>
<h2><span class="Italics">Carcinogenesis, Mutagenesis, and Impairment of Fertility:</span></h2>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.</p>
<br><p>Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.5"></a><p></p>
<h2><span class="Italics">Pregnancy Category C:</span></h2>
<p class="First">Corticosteroids are generally teratogenic in laboratory animals
                           when administered systemically at relatively low dosage levels. The more
                           potent corticosteroids have been shown to be teratogenic after dermal
                           application in laboratory animals. There are no adequate and
                           well-controlled studies in pregnant women on teratogenic effects from
                           topically applied corticosteroids. Therefore, topical corticosteroids
                           should be used during pregnancy only if the potential benefit justifies
                           the potential risk to the fetus. Drugs of this class should not be used
                           extensively on pregnant patients, in large amounts, or for prolonged
                           periods of time.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.6"></a><p></p>
<h2><span class="Italics">Nursing Mothers:</span></h2>
<p class="First">It is not known whether topical administration of corticosteroids
                           could result in sufficient systemic absorption to produce detectable
                           quantities in breast milk. Systemically administered corticosteroids are
                           secreted into breast milk in quantities not likely to have deleterious
                           effect on the infant. Nevertheless, caution should be exercised when
                           topical corticosteroids are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="pediatric"></a><a name="section-6.7"></a><p></p>
<h2><span class="Italics">Pediatric Use:</span></h2>
<p class="First">Pediatric patients may demonstrate greater susceptibility to
                           topical corticosteroid-induced HPA axis suppression and Cushing's
                           syndrome than mature patients because of a larger skin surface area body
                           weight ratio. </p>
<br><p>Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's
                           syndrome, and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> have been reported in children
                           receiving topical corticosteroids. Manifestations of adrenal suppression
                           in children include linear <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, delayed <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, low
                           plasma cortisol levels, and absence of response to ACTH stimulation.
                           Manifestations of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> include bulging fontanelles,
                           <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and bilateral <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>.</p>
<br><p>Administration of topical corticosteroids to children should be
                           limited to the least amount compatible with an effective therapeutic
                           regimen. Chronic corticosteroid therapy may interfere with the growth and
                           development of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">The following local adverse reactions are reported infrequently with
                     topical corticosteroids, but may occur more frequently with the use of
                     occlusive dressings. These reactions are listed in an approximate decreasing
                     order of occurrence:</p>
<dl>
<dt> </dt>
<dd>Burning</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></dd>
<dt> </dt>
<dd>Irritation</dd>
<dt> </dt>
<dd>Dryness</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">Folliculitis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">Hypertrichosis</span></dd>
<dt> </dt>
<dd>Acneform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span></dd>
<dt> </dt>
<dd>Hypopigmentation</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">Perioral dermatitis</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic contact dermatitis</span></dd>
<dt> </dt>
<dd>Maceration of the skin</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">Secondary infection</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">Skin atrophy</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">Striae</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">Miliaria</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">Apply Cloderm (clocortolone pivalate) Cream 0.1% sparingly to the affected areas three times a day and rub in gently.</p>
<br><p>Occlusive dressings may be used for the management of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or recalcitrant conditions. </p>
<br><p>If an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops, the use of occlusive dressings should be discontinued and appropriate anti-microbial therapy instituted.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Cloderm (clocortolone pivalate) Cream 0.1% is supplied in 30 gram and 75 gram pump bottles, 45 gram and 90 gram tubes.</p>
<a name="table2"></a><table width="50%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="60%">
<tbody class="Headless">
<tr class="Botrule First Toprule">
<td class="Lrule Rrule" align="center">30 gram pump bottle</td>
<td class="Rrule" align="center">NDC 67857-804-30</td>
</tr>
<tr class="Botrule Toprule">
<td class="Lrule Rrule" align="center">75 gram pump bottle</td>
<td class="Rrule" align="center">NDC 67857-804-51</td>
</tr>
<tr class="Botrule Toprule">
<td class="Lrule Rrule" align="center">45 gram tube</td>
<td class="Rrule" align="center">NDC 67857-804-45</td>
</tr>
<tr class="Botrule Last Toprule">
<td class="Lrule Rrule" align="center">90 gram tube</td>
<td class="Rrule" align="center">NDC 67857-804-90</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11"></a><p></p>
<h1>STORAGE:</h1>
<p class="First">Store Cloderm Cream between 15° and 30° C (59° and 86° F). Avoid freezing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Distributed by:</p>
<p>PROMIUS<span class="Sup">®</span> Pharma<br>UNLIMITED POSSIBILITIES</p>
<p>www.promiuspharma.com</p>
<p>Promius Pharma, LLC<br>200 Somerset Corporate Blvd., Floor 7<br>Bridgewater, NJ 08807</p>
<p><span class="Bold">Cloderm<span class="Sup">®</span></span> is a trademark of Coria Laboratories, LTD.</p>
<br><p>Manufactured by: <br>DPT LABORATORIES, LTD. <br>San Antonio, Texas 78215</p>
<br><br><p>Issued 0711</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 30 gram Pump Bottle Carton</h1>
<p class="First">NDC 67857-804-30<br><span class="Bold">Rx ONLY</span><br>For Topical Use Only</p>
<p><span class="Bold">Cloderm</span><span class="Sup">®</span><br>(clocortolone pivalate)<br>Cream, 0.1%</p>
<p><span class="Italics">Pump</span></p>
<p><span class="Bold">Net Wt 30 g</span></p>
<p><span class="Bold">PROMIUS</span><span class="Sup">®</span><br>PHARMA</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 30 gram Pump Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4abc01f2-03d4-43d5-a085-f452443cfca2&amp;name=cloderm-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLODERM 		
					</strong><br><span class="contentTableReg">clocortolone pivalate cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67857-804</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>clocortolone pivalate</strong> (clocortolone) </td>
<td class="formItem">clocortolone pivalate</td>
<td class="formItem">0.001 g  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYOXYL 40 STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE B</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67857-804-30</td>
<td class="formItem">30 g in 1 BOTTLE, PUMP</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:67857-804-45</td>
<td class="formItem">45 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:67857-804-51</td>
<td class="formItem">75 g in 1 BOTTLE, PUMP</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:67857-804-90</td>
<td class="formItem">90 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017765</td>
<td class="formItem">08/22/1977</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Promius Pharma, LLC
							(020408265)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Promius Pharma, LLC (020408265)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">DPT Laboratories, LTD</td>
<td class="formItem"></td>
<td class="formItem">832224526</td>
<td class="formItem">MANUFACTURE(67857-804)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>903dbe4b-2e34-4359-a442-baf4e96c0dac</div>
<div>Set id: 4abc01f2-03d4-43d5-a085-f452443cfca2</div>
<div>Version: 3</div>
<div>Effective Time: 20120830</div>
</div>
</div> <div class="DistributorName">Promius Pharma, LLC</div></p>
</body></html>
